Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.

Beatrice DettiSilvia ScocciantiMaria Ausilia TeriacaVirginia MaragnaVictoria LorenzettiSara LucidiChiara BelliniDaniela GretoIsacco DesideriLorenzo Livi

Published in: La Radiologia medica (2021)

Our analysis confirms the efficacy of bevacizumab in recurrent high-grade glioma patients with an acceptable toxicity profile, in keeping with its known safety in the literature.

Keyphrases

high grade
low grade
end stage renal disease
ejection fraction
systematic review
newly diagnosed
chronic kidney disease
prognostic factors
oxidative stress
peritoneal dialysis
metastatic colorectal cancer
data analysis